Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study

BACKGROUND: Nintedanib slows lung function decline for patients with non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis (PPF) in clinical trials, but the real-world safety and efficacy are not known. METHODS: In this retrospective cohort study, standardised data were collected from pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Raman, Lavanya, Stewart, Iain, Barratt, Shaney L., Chua, Felix, Chaudhuri, Nazia, Crawshaw, Anjali, Gibbons, Michael, Hogben, Charlotte, Hoyles, Rachel, Kouranos, Vasilis, Martinovic, Jennifer, Mulholland, Sarah, Myall, Katherine J., Naqvi, Marium, Renzoni, Elisabetta A., Saunders, Peter, Steward, Matthew, Suresh, Dharmic, Thillai, Muhunthan, Wells, Athol U., West, Alex, Mitchell, Jane A., George, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026008/
https://www.ncbi.nlm.nih.gov/pubmed/36949962
http://dx.doi.org/10.1183/23120541.00423-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026008/
https://www.ncbi.nlm.nih.gov/pubmed/36949962
http://dx.doi.org/10.1183/23120541.00423-2022

Ejemplares similares